Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR2 C383R |
| Therapy | Erdafitinib |
| Indication/Tumor Type | cholangiocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 C383R | cholangiocarcinoma | predicted - sensitive | Erdafitinib | Case Reports/Case Series | Actionable | In a retrospective analysis, Balversa (erdafitinib) treatment resulted in a partial response with a progression-free survival of 9.3 months in a cholangiocarcinoma patient harboring FGFR2 C383R (PMID: 39706336; NCT01703481). | 39706336 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39706336) | A Model for Decoding Resistance in Precision Oncology: Acquired Resistance to FGFR inhibitors in Cholangiocarcinoma. | Full reference... |